Travere Therapeutics (TVTX) Interest Expenses (2011 - 2026)

Travere Therapeutics' Interest Expenses history runs 16 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• Quarterly Interest Expenses fell 20.69% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (up 14.26% YoY) and the FY2025 annual result came in at $370.6 million, up 7.68% from the prior year.
• Interest Expenses was $2.3 million for Q1 2026 at Travere Therapeutics, up from $2.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $21.8 million in Q2 2025 and bottomed at $438000.0 in Q4 2024.
• A 5-year average of $3.7 million and a median of $2.8 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses slumped 84.36% — and 2025, when it soared 683.11%.
• Travere Therapeutics' Interest Expenses stood at $2.8 million in 2022, then slipped by 0.5% to $2.8 million in 2023, then plunged by 84.36% to $438000.0 in 2024, then jumped by 413.24% to $2.2 million in 2025, then grew by 2.31% to $2.3 million in 2026.
• Business Quant data shows TVTX's Interest Expenses at $2.3 million in Q1 2026, $2.2 million in Q4 2025, and $2.8 million in Q3 2025.